Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering clinical-stage gene editing company dedicated to revolutionizing medicine through the use of CRISPR-based therapies. Founded in 2014 by Caribou Biosciences and Atlas Venture, along with leading scientists in the field, Intellia harnesses the potential of CRISPR/Cas9 technology to develop curative treatments for a variety of genetically defined diseases.
The company's core mission is to leverage CRISPR/Cas9—an innovative technology adapted from a natural cellular process that allows for precise and flexible gene editing. This technology enables the correction of specific DNA sequences within any organism, opening new frontiers in biomedical research and clinical interventions.
Intellia's portfolio includes both in vivo and ex vivo gene editing programs. The in vivo programs aim to edit disease-causing genes directly within the human body, targeting conditions such as ATTR amyloidosis, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Notable achievements include the interim results from their NTLA-2002 program for HAE, which showed a 95% reduction in monthly attack rates, with most patients remaining attack-free.
The ex vivo programs focus on engineering human cells outside the body to treat cancer and autoimmune diseases. These programs include collaborations with prominent companies like Regeneron and Novartis, which help advance their therapeutic pipeline.
Intellia's financial condition reflects its robust pipeline and strategic partnerships. The company recently reported strong enrollment progress in their pivotal Phase 3 MAGNITUDE trial for NTLA-2001 targeted at ATTR amyloidosis with cardiomyopathy. They have also formed a strategic collaboration with ReCode Therapeutics to develop treatments for cystic fibrosis, utilizing ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform.
Committed to advancing the field of gene editing, Intellia continues to expand its CRISPR-based platform with novel editing and delivery technologies. The company remains at the forefront of a new era in medicine, as evidenced by its ongoing clinical trials and promising preliminary data.
For more detailed information and the latest updates, investors and stakeholders are encouraged to visit www.intelliatx.com and follow Intellia on Twitter @intelliatx.
Intellia Therapeutics (NASDAQ:NTLA) has priced a public offering of 6,550,219 shares at $45.80 each, aiming to raise approximately $300 million. The underwriter, Goldman Sachs, has a 30-day option for an additional 982,532 shares. The offering is set to close around December 2, 2022, based on standard conditions. The shares are offered under an existing SEC registration statement. Intellia specializes in CRISPR-based genome editing therapies, focusing on potential cures for diseases through innovative therapeutic approaches.
Intellia Therapeutics (NASDAQ: NTLA) announced a public offering of $250 million in common stock, with a potential additional 15% option for underwriters. Goldman Sachs & Co. LLC is the sole underwriter. The offering is subject to market conditions and follows an effective shelf registration with the SEC. A preliminary prospectus will be available soon. The funds raised are intended to enhance Intellia's development of CRISPR-based therapies. However, there is no guarantee on the offering's completion or terms.
Intellia Therapeutics has released promising interim data from its Phase 1/2 clinical trial of NTLA-2002, a CRISPR-based therapy for hereditary angioedema (HAE). Results show robust reductions in plasma kallikrein levels and HAE attack rates across all tested doses. Notably, patients in the 25 mg and 75 mg cohorts remain attack-free through the latest follow-up, with intervals lasting between 5.5 to 10.6 months. The treatment was well-tolerated, with no serious adverse effects reported. An investor event discussing these findings is scheduled for November 14, 2022.
Intellia Therapeutics (NASDAQ:NTLA) has presented interim results from its Phase 1 trial of NTLA-2001, a CRISPR-based treatment for ATTR amyloidosis with cardiomyopathy. Results showed a remarkable 90% mean serum TTR reduction following a single dose, sustained for four to six months. NTLA-2001 was generally well-tolerated, with minimal adverse reactions. This study marks a significant step in exploring the potential of NTLA-2001 to permanently inactivate the TTR gene, offering a promising future for patients with this life-threatening condition.
Intellia Therapeutics (NTLA) reported significant interim results from its clinical trials for NTLA-2001 and NTLA-2002 in the third quarter of 2022. NTLA-2001 showed mean serum transthyretin protein reductions of 93% and 92% at doses of 0.7 mg/kg and 1.0 mg/kg, respectively. The firm has strong cash reserves of $848.7 million and expects to initiate Phase 2 of NTLA-2002 by early 2023. Collaboration revenue increased to $13.3 million, while R&D expenses rose to $96.7 million. The net loss was reported at $113.2 million, indicating an increase compared to the previous year.
Intellia Therapeutics (NASDAQ: NTLA) announced new interim clinical data from its Phase 1/2 study of NTLA-2002, showcasing safety, kallikrein reduction, and attack rate information. This investigational CRISPR/Cas9 therapy aims to prevent angioedema attacks in hereditary angioedema (HAE) patients. Key presentation details include:
- Date: Nov 12, 2022
- Presenter: Dr. Hilary Longhurst
A live webcast to discuss the data will be held on Nov 14, 2022. NTLA-2002 represents a novel approach to a rare genetic disorder affecting 1 in 50,000 people.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present its Q3 2022 financial results and operational highlights on a conference call scheduled for November 3, 2022, at 8 a.m. ET. Investors can participate by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will also be available on the company’s website. Intellia focuses on developing genome editing therapies through CRISPR technology, aiming to address various diseases with its in vivo and ex vivo programs.
Intellia Therapeutics (NASDAQ:NTLA) announced upcoming presentations at two investor conferences in October 2022. The Chardan’s 6th Annual Genetic Medicines Conference is scheduled for October 3, 2022, at 8:30 a.m. ET in a fireside chat format. The 2022 Truist Securities Genetic Medicine Summit will include a genome editing panel on October 20, 2022, at 9:00 a.m. ET. A live webcast of the Chardan presentation will be available on Intellia's website, with a replay accessible for 30 days.
Intellia Therapeutics announced promising interim results from the Phase 1 study of NTLA-2001, a CRISPR/Cas9 therapy for transthyretin (ATTR) amyloidosis. At doses of 0.7 mg/kg and 1.0 mg/kg, mean serum transthyretin (TTR) reductions of 93% and 92% were observed at day 28. The treatment was well-tolerated, with transitory infusion reactions as the only adverse events. These outcomes suggest NTLA-2001 may provide a single-dose treatment option for patients with cardiomyopathy manifestations of ATTR amyloidosis. Further discussions on this data are scheduled for an investor event today.
Intellia Therapeutics and Regeneron Pharmaceuticals announced promising interim results from the Phase 1 study of NTLA-2001, a CRISPR therapy for transthyretin (ATTR) amyloidosis. The trial exhibited significant mean serum transthyretin reductions of 93% and 92% at doses of 0.7 mg/kg and 1.0 mg/kg, respectively, on day 28. The treatment was well-tolerated, with minimal adverse reactions. Follow-ups indicated sustained reductions over two to six months. Intellia plans to expand the study with a fixed dose of 0.7 mg/kg and aims for a pivotal trial, potentially including U.S. patients.
FAQ
What is the current stock price of Intellia Therapeutics (NTLA)?
What is the market cap of Intellia Therapeutics (NTLA)?
What is the mission of Intellia Therapeutics?
What diseases is Intellia targeting with their CRISPR-based therapies?
What are Intellia's key advancements in hereditary angioedema (HAE) treatment?
When was Intellia Therapeutics founded?
Who are Intellia's key collaborators?
What is CRISPR/Cas9?
How does Intellia's in vivo program work?
What are the recent financial highlights of Intellia Therapeutics?
What is the scope of Intellia's collaboration with ReCode Therapeutics?
Where can I find more information about Intellia Therapeutics?
